Cancer · 1971 · 92 citations · 8 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyOncology PharmacotherapyAdverse Effects Of ChemotherapyChemotherapy Drug AdministrationChemotherapy Toxicity ManagementOncology PharmacologyToxicity ClassificationToxicity Management5-Fluorouracil Therapy5-Fluorouracil TreatmentChemotherapy-related ToxicityCumulative Dose AssessmentCumulative Dose EvaluationHematologic Toxicity AssessmentIntravenous Chemotherapy DosingOral Fluoropyrimidines
One hundred seven patients with disseminated adenocarcinoma were randomized to receive 5-Fluorouracil (5-FU) by vein, Group A (52 patients), or by mouth, Group B (55 patients). Dosage for both groups was 15 mg/kg body weight given once weekly. Clinically useful response rate was 21% for Group A (IV) and 40% for Group B (oral). Duration of response and mean cumulative dose to beginning response were comparable in both groups. Slight differences were observed in toxicities in the 2 groups. G.I. toxicity was more frequent in Group B (oral) and hematologic toxicity was more common in Group A (IV).
8
Five Years Clinical Experience with 5-Fluorouracil
Fred J. Ansfield · JAMA · 1962 · 218 citations
Medicine, Oncology, Pharmacology +14
5-Fluorouracil in Cancer: An Improved Regimen
John Horton · Annals of Internal Medicine · 1970 · 79 citations
Medicine, Oncology, Pharmacotherapy +17
A Less Toxic Fluorouracil Dosage Schedule
Fred J. Ansfield · JAMA · 1964 · 47 citations
Medicine, Oncology, Pharmacology +16